Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01372137
Other study ID # SNOXH94C001
Secondary ID 2011-000705-46
Status Completed
Phase Phase 1
First received June 8, 2011
Last updated January 22, 2016
Start date July 2011
Est. completion date March 2012

Study information

Verified date June 2014
Source NOXXON Pharma AG
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This is the first clinical trial with NOX-H94. The purpose of this clinical trial is to identify a safe and efficacious treatment regimen for the clinical development of NOX-H94 in patients with anemia of chronic disease (inflammation).


Description:

NOX H94 is a pegylated Spiegelmer that specifically binds to human hepcidin, thereby antagonizing its role in hemostasis, and is therefore indicated for use in anemia of inflammation. Human hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. Hepcidin expression in hepatocytes is regulated by multiple, in particular opposing signals, including systemic iron availability, hepatic iron stores, erythropoietic activity, hypoxia, and inflammatory states. These different signals are integrated transcriptionally. In chronic inflammation, such as occurs in rheumatoid arthritis, chronic kidney disease or cancer, elevated hepcidin levels have been measured and may be a key factor leading to anemia in these patients.

NOX-H94 is therefore indicated for treatment of patients with an anemia of inflammation, which is characterized by increased intracellular iron stores, increased serum ferritin concentrations and reduced sensitivity to treatment with erythropoiesis stimulating agents (ESAs), due to the limited availability of serum iron. Antagonism of hepcidin by NOX-H94 therefore leads to elevated levels of iron and transferrin saturation in the peripheral blood and could supply iron for erythropoiesis thereby correcting the anemia.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria

- Male subjects or female subjects of non-childbearing potential (Groups A to E), male subjects (groups F to H)

- Age 18-65 years

- Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters

- Males willing to use 2 means of contraceptive methods for at least 2 months after the final examination

Exclusion Criteria:

1. Anemia predominantly caused by other factors than chronic disease.

2. Iron overload or disturbances in utilization of iron.

3. Intravenous iron treatment or blood transfusion within 4 weeks prior to screening visit.

4. Erythropoietin treatment within 4 weeks prior to screening visit.

5. Intake of Intravenous iron, Blood transfusions, Erythropoietin during their trial participation.

6. Resting supine pulse rate < 40 or > 100 beats / min.

7. Resting supine blood pressure:

Systolic blood pressure < 90 or > 160 mmHg Diastolic blood pressure < 40 or > 100 mmHg.

8. History or presence of confirmed orthostatic hypotension defined.

9. Positive test of HIV type 1/2 antibodies, HBs antigen, HBc antibodies, HCV antibodies.

10. Participation in another clinical trial during the last 3 months before starting this trial.

11. Positive test for drugs of abuse.

12. Diseases or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.

13. Marked repolarization abnormality.

14. Current bronchial asthma, childhood asthma which has been resolved is allowed.

15. Definite or suspected history of drug allergy or hypersensitivity or intolerance to PEG

16. Regular intake of over 14 units of alcohol per week for women and 21 units for men.

17. Not able to abstain from consumption of:

- Caffeine containing beverages or food (tea, coffee, cola, chocolate, etc.)

- Quinine containing beverages or food (bitter lemon, tonic water)

- Grapefruit juice (sweet or sour)

- Poppy seeds containing beverages or food

18. Subjects who have donated any blood, plasma or platelets in the month prior to screening

19. History of seizures or at risk

20. Known or suspected of not being able to comply with the trial protocol and/or clinical unit restrictions.

21. History of or presence of clinically significant diseases other than the underlying disease.

22. Surgery or trauma with significant blood loss within the last 2 months before administration of study drug.

28. History of increased bleeding risk.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
NOX-H94
Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
Other:
Glucose 5%
Placebo

Locations

Country Name City State
United Kingdom HMR London

Sponsors (1)

Lead Sponsor Collaborator
NOXXON Pharma AG

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events 0 to 90 days Yes
Secondary drug plasma concentrations 0 to 29 days No
See also
  Status Clinical Trial Phase
Completed NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A